André B P van Kuilenburg 1, Hanna Mandel 2, Tameemi Abdalla Moady 3, Ronen Sloma 4, Ayalla Fedida 2, René Leen 5, Judith Jansen-Meijer 5, Tamar Paperna 3, Vered Fleisher Sheffer 6, Doreen Dobritzsch 7, Ori Hochwald 8, Nicole N van der Wel 9, Anita E Grootemaat 9, Semyon Chulsky 10, Mika S Rootman 10, Ayelet Eran 11, Maha A Yousef 12, April Dinwiddie 13, Joshua Manor 14, Clara D M Van Karnebeek 15, Limor Kalfon 2, Tova Hershkovitz 2, Galit Tal 16, Tzipora C Falik Zaccai 17
Abstract
Glutaminase deficiency has recently been identified as a novel inherited metabolic disorder with a broad phenotypic spectrum ranging from early-onset global developmental delay to lethal early neonatal encephalopathy. We describe three infants from two unrelated families who presented clinically with neonatal onset refractory burst-suppression epileptic encephalopathy and respiratory failure, progressing to either a persistent vegetative state or early death. One patient remains alive at the age of six years. Metabolic investigations demonstrated elevated glutamine concentrations in cerebrospinal fluid and increased serum alanine and glutamine levels, biochemical features characteristic of urea cycle disorders, while ammonia levels remained within the normal range. Notably, brain magnetic resonance imaging revealed cystic lesions resembling the neuroimaging findings typically observed in patients with urea cycle defects. Exome sequencing identified a homozygous, unreported missense variant in GLS (NM_014905.5:c.1174G > A; p.Gly392Arg) in both siblings from family 1, and a novel homozygous missense variant (NM_014905.5:c.1031 T > C; p.Leu344Pro) in the proband from family 2. Functional studies of patient fibroblasts and recombinantly expressed mutant glutaminase protein, demonstrated a complete glutaminase deficiency. In addition, patient-derived fibroblasts exhibited pronounced ultrastructural abnormalities, including nuclear dysmorphisms, lysosomal dysfunction with glycogen accumulation, ER stress, Golgi disruption, and mitochondrial fragmentation, along with altered cellular bioenergetics characterized by impaired mitochondrial respiratory function. The biochemical and clinical findings in our patients support a key role for elevated glutamine in the neuropathogenesis of both glutaminase-deficient patients and individuals with hepatic encephalopathy and/or urea cycle defects.
Keywords: Encephalopathy; GLS; Glutaminase deficiency; Glutamine; Hyperammonemia.
- Amsterdam UMC, Vrije Universiteit Amsterdam, University of Amsterdam, Emma Center for Personalized Medicine, Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands. Electronic address: a.b.vankuilenburg@amsterdamumc.nl.
- Institute of Human Genetics, Galilee Medical Center, Naharia, Israel.
- The Genetics Institute Rambam Health Care Center, Haifa, Israel.
- Bnei Zion Medical Center, Simon Winter Institute for Human Genetics, Haifa, Israel.
- Amsterdam UMC, Vrije Universiteit Amsterdam, University of Amsterdam, Emma Center for Personalized Medicine, Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
- The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Uppsala University, Department of Pharmacy, Uppsala, Sweden.
- Department of Neonatology and Neonatal Intensive Care, Rambam Health Care Campus, Haifa, Israel; The Technion Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
- Amsterdam UMC, Electron Microscopy Center Amsterdam, Medical Biology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
- Department of Diagnostic Imaging, Rambam Health Care Campus, Haifa, Israel.
- The Technion Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; Department of Diagnostic Imaging, Rambam Health Care Campus, Haifa, Israel.
- Kupat Holim Meuhedet, Northern District, Israel.
- CeGaT GmbH laboratory, Tübingen, Germany.
- Institute of Human Genetics, Galilee Medical Center, Naharia, Israel; Edmond and Lily Safra children’s Hospital, Sheba Medical Center, Ramat Gan, Israel.
- Amsterdam UMC, Vrije Universiteit Amsterdam, University of Amsterdam, Emma Center for Personalized Medicine, Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; United for Metabolic Diseases, the Netherlands.
- The Technion Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; Metabolic Clinic and Pediatric Department “B”, Ruth Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa 3109601, Israel.
- Institute of Human Genetics, Galilee Medical Center, Naharia, Israel; Azrielli Faculty of Medicine, Bar Ilan, Safed, Israel. Electronic address: Tzipora.Falik-Zaccai@biu.ac.il.
